{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:27Z","timestamp":1789398147407,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00568-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:58:18Z","timestamp":1783940298000},"page":"409-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre\u2013existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18\u201330 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3909","authenticated-orcid":false,"given":"Mohammed Salah","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-2274","authenticated-orcid":false,"given":"Yola","family":"Moride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-0779","authenticated-orcid":false,"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"568_CR1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/S0140-6736(22)00791-7","volume":"399","author":"H-L Wong","year":"2022","unstructured":"Wong H-L, Hu M, Zhou CK, et\u00a0al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet Lond Engl. 2022;399:2191\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(22)00791-7.","journal-title":"Lancet Lond Engl"},{"key":"568_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cjca.2022.12.003","volume":"39","author":"M Zuin","year":"2023","unstructured":"Zuin M, Rigatelli G, Bilato C, et\u00a0al. One-year risk of myocarditis after COVID-19 infection: a systematic review and meta-analysis. Can J Cardiol. 2023;39:839\u201344. https:\/\/doi.org\/10.1016\/j.cjca.2022.12.003.","journal-title":"Can J Cardiol"},{"key":"568_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/heartjnl-2014-306362","volume":"101","author":"M Imazio","year":"2015","unstructured":"Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart. 2015;101:1159\u201368. https:\/\/doi.org\/10.1136\/heartjnl-2014-306362.","journal-title":"Heart"},{"key":"568_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","volume":"12","author":"A Pollack","year":"2015","unstructured":"Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis\u2014Diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12:670\u201380. https:\/\/doi.org\/10.1038\/nrcardio.2015.108.","journal-title":"Nat Rev Cardiol"},{"key":"568_CR5","doi-asserted-by":"publisher","first-page":"e2218505","DOI":"10.1001\/jamanetworkopen.2022.18505","volume":"5","author":"SA Buchan","year":"2022","unstructured":"Buchan SA, Seo CY, Johnson C, et\u00a0al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open. 2022;5:e2218505. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.18505.","journal-title":"JAMA Netw Open"},{"key":"568_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","volume":"7","author":"\u00d8 Karlstad","year":"2022","unstructured":"Karlstad \u00d8, Hovi P, Husby A, et\u00a0al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022;7:600\u201312. https:\/\/doi.org\/10.1001\/jamacardio.2022.0583.","journal-title":"JAMA Cardiol"},{"key":"568_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","volume":"327","author":"ME Oster","year":"2022","unstructured":"Oster ME, Shay DK, Su JR, et\u00a0al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327:331\u201340. https:\/\/doi.org\/10.1001\/jama.2021.24110.","journal-title":"JAMA"},{"key":"568_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065687","volume":"13","author":"A Alami","year":"2023","unstructured":"Alami A, Krewski D, Farhat N, et\u00a0al. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. BMJ Open. 2023;13:e065687. https:\/\/doi.org\/10.1136\/bmjopen-2022-065687.","journal-title":"BMJ Open"},{"key":"568_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13947","author":"B Knudsen","year":"2023","unstructured":"Knudsen B, Prasad V. COVID\u201019 vaccine induced myocarditis in young males: a systematic review. Eur J Clin Investig. 2023. https:\/\/doi.org\/10.1111\/eci.13947.","journal-title":"Eur J Clin Investig"},{"key":"568_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5744","volume":"10","author":"S Hassanzadeh","year":"2022","unstructured":"Hassanzadeh S, Sadeghi S, Mirdamadi A, Nematollahi A. Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID-19 vaccination: a case report. Clin Case Rep. 2022;10:e05744. https:\/\/doi.org\/10.1002\/ccr3.5744.","journal-title":"Clin Case Rep"},{"key":"568_CR11","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1097\/MJT.0000000000001472","volume":"29","author":"R Singh","year":"2022","unstructured":"Singh R, Chakrabarti SS, Gambhir IS, et\u00a0al. Acute cardiac events after ChAdOx1 nCoV-19 corona virus vaccine: report of three cases. Am J Ther. 2022;29:e579\u201385. https:\/\/doi.org\/10.1097\/MJT.0000000000001472.","journal-title":"Am J Ther"},{"key":"568_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-024-00893-1","volume":"9","author":"A Buoninfante","year":"2024","unstructured":"Buoninfante A, Andeweg A, Genov G, Cavaleri M. Myocarditis associated with COVID-19 vaccination. NPJ Vaccines. 2024;9:1\u20138. https:\/\/doi.org\/10.1038\/s41541-024-00893-1.","journal-title":"NPJ Vaccines"},{"key":"568_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh3455","volume":"8","author":"A Barmada","year":"2023","unstructured":"Barmada A, Klein J, Ramaswamy A, et\u00a0al. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine\u2013associated myocarditis. Sci Immunol. 2023;8:eadh3455. https:\/\/doi.org\/10.1126\/sciimmunol.adh3455.","journal-title":"Sci Immunol"},{"key":"568_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10040611","volume":"10","author":"J Moosmann","year":"2022","unstructured":"Moosmann J, Gentles T, Occleshaw C, Mitchelson B. COVID vaccine-associated myocarditis in adolescent siblings: does it run in the family? Vaccines (Basel). 2022;10:611. https:\/\/doi.org\/10.3390\/vaccines10040611.","journal-title":"Vaccines (Basel)"},{"key":"568_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq0143","volume":"17","author":"X Cao","year":"2025","unstructured":"Cao X, Manhas A, Chen Y-I, et\u00a0al. Inhibition of CXCL10 and IFN-\u03b3 ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination. Sci Transl Med. 2025;17:eadq0143. https:\/\/doi.org\/10.1126\/scitranslmed.adq0143.","journal-title":"Sci Transl Med"},{"key":"568_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2318","volume":"32","author":"A Fazlollahi","year":"2022","unstructured":"Fazlollahi A, Zahmatyar M, Noori M, et\u00a0al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2022;32:e2318. https:\/\/doi.org\/10.1002\/rmv.2318.","journal-title":"Rev Med Virol"},{"key":"568_CR17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/jmv.27501","volume":"94","author":"W Woo","year":"2022","unstructured":"Woo W, Kim AY, Yon DK, et\u00a0al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. J Med Virol. 2022;94:1566\u201380. https:\/\/doi.org\/10.1002\/jmv.27501.","journal-title":"J Med Virol"},{"key":"568_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pds.3918","volume":"25","author":"O Mahaux","year":"2016","unstructured":"Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed\u2010to\u2010expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215\u201322. https:\/\/doi.org\/10.1002\/pds.3918.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"568_CR19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36090","volume":"15","author":"D Quayson","year":"2023","unstructured":"Quayson D, Alston M, Fabbri S. Observed versus expected distribution of patient self-reported race and ethnicity in quality improvement review processes at a single safety net academic institution. Cureus. 2023;15:e36090. https:\/\/doi.org\/10.7759\/cureus.36090.","journal-title":"Cureus"},{"key":"568_CR20","doi-asserted-by":"publisher","first-page":"e2133205","DOI":"10.1001\/jamanetworkopen.2021.33205","volume":"4","author":"CM Aldrighetti","year":"2021","unstructured":"Aldrighetti CM, Niemierko A, Van Allen E, et\u00a0al. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open. 2021;4:e2133205. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33205.","journal-title":"JAMA Netw Open"},{"key":"568_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S2352-4642(20)30215-7","volume":"4","author":"P Davies","year":"2020","unstructured":"Davies P, Evans C, Kanthimathinathan HK, et\u00a0al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020;4:669\u201377. https:\/\/doi.org\/10.1016\/S2352-4642(20)30215-7.","journal-title":"Lancet Child Adolesc Health"},{"key":"568_CR22","unstructured":"Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), U.S. Department of Health and Human Services (HHS) VAERS\u2014Data sets. In: vaccine adverse event report. Syst. VAERS. https:\/\/vaers.hhs.gov\/data\/datasets.html. Accessed 8 Mar 2025."},{"key":"568_CR23","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1016\/S0264-410X(99)00132-2","volume":"17","author":"JA Singleton","year":"1999","unstructured":"Singleton JA, Lloyd JC, Mootrey GT, et\u00a0al. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine. 1999;17:2908\u201317. https:\/\/doi.org\/10.1016\/S0264-410X(99)00132-2.","journal-title":"Vaccine"},{"key":"568_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28391","volume":"4","author":"Y Young-Xu","year":"2021","unstructured":"Young-Xu Y, Korves C, Roberts J, et\u00a0al. Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US veterans. JAMA Netw Open. 2021;4:e2128391. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28391.","journal-title":"JAMA Netw Open"},{"key":"568_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/CIRCULATIONAHA.118.035550","volume":"139","author":"SAE Peters","year":"2019","unstructured":"Peters SAE, Muntner P, Woodward M. Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016. Circ. 2019;139:1025\u201335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035550.","journal-title":"Circ"},{"key":"568_CR26","unstructured":"Centers for Disease Control and Prevention (2023) COVID-19 vaccinations in the United States. In: Cent. Dis. Control Prev. https:\/\/covid.cdc.gov\/covid-data-tracker. Accessed 28 Nov 2023."},{"key":"568_CR27","unstructured":"Dean AG, Soe MM, Kevin M. Sullivan, Mir RA SMR and confidence intervals. In: OpenEpi open source epidemiol. Stat. Public Health Version WwwOpenEpicom. https:\/\/www.openepi.com\/SMR\/SMR.htm. Accessed 28 Nov 2025."},{"key":"568_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061126","volume":"12","author":"A Ostropolets","year":"2022","unstructured":"Ostropolets A, Hripcsak G. COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study. BMJ Open. 2022;12:e061126. https:\/\/doi.org\/10.1136\/bmjopen-2022-061126.","journal-title":"BMJ Open"},{"key":"568_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059994","volume":"12","author":"JE Ebinger","year":"2022","unstructured":"Ebinger JE, Joung S, Liu Y, et\u00a0al. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open. 2022;12:e059994. https:\/\/doi.org\/10.1136\/bmjopen-2021-059994.","journal-title":"BMJ Open"},{"key":"568_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, et\u00a0al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(21)02183-8.","journal-title":"Lancet"},{"key":"568_CR31","doi-asserted-by":"crossref","unstructured":"Bryan S, Afful J, Carroll M, et\u00a0al (2021) NHSR 158. National Health and Nutrition Examination Survey 2017\u2013March 2020 pre-pandemic data files. National Center for Health Statistics (U.S.).","DOI":"10.15620\/cdc:106273"},{"key":"568_CR32","unstructured":"Ostchega Y, Fryar C, Nwankwo T, Nguyen D (2020) Hypertension prevalence among adults aged 18 and over: United States, 2017\u20132018."},{"key":"568_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.33730","volume":"5","author":"SM Hosseini-Moghaddam","year":"2022","unstructured":"Hosseini-Moghaddam SM, He S, Calzavara A, et\u00a0al. Association of influenza vaccination with SARS-CoV-2 infection and associated hospitalization and mortality among patients aged 66 years or older. JAMA Netw Open. 2022;5:e2233730. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.33730.","journal-title":"JAMA Netw Open"},{"key":"568_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jclinepi.2008.06.014","volume":"62","author":"JC Nelson","year":"2009","unstructured":"Nelson JC, Jackson ML, Weiss NS, Jackson LA. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol. 2009;62:687\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.06.014.","journal-title":"J Clin Epidemiol"},{"key":"568_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1154-y","volume":"15","author":"C Remschmidt","year":"2015","unstructured":"Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015;15:429. https:\/\/doi.org\/10.1186\/s12879-015-1154-y.","journal-title":"BMC Infect Dis"},{"key":"568_CR36","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.1016\/j.eurpsy.2017.02.377","volume":"41","author":"M Gahr","year":"2017","unstructured":"Gahr M, Eller J, Connemann BJ, Sch\u00f6nfeldt-Lecuona C. Underreporting of adverse drug reactions: results from a survey among physicians. Eur Psychiatry. 2017;41:S369. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.02.377.","journal-title":"Eur Psychiatry"},{"key":"568_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions\u202f: a systematic review. Drug Saf. 2006;29:385\u201396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003.","journal-title":"Drug Saf"},{"key":"568_CR38","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","volume":"33","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33:4398\u2013405. https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.035.","journal-title":"Vaccine"},{"key":"568_CR39","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.vaccine.2019.02.046","volume":"37","author":"J Mouchet","year":"2019","unstructured":"Mouchet J, B\u00e9gaud B. Hepatitis B vaccination and central demyelination \u2013 History, description and observed\/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period. Vaccine. 2019;37:2142\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.046.","journal-title":"Vaccine"},{"key":"568_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Potteg\u00e5rd","year":"2021","unstructured":"Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, et\u00a0al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. https:\/\/doi.org\/10.1136\/bmj.n1114.","journal-title":"BMJ"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00568-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:03:01Z","timestamp":1789394581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00568-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00568-4","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"25 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No institutional review board oversight was required as the data used was publicly available and deidentified.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}